Q4 Earnings Estimate for McKesson Issued By Leerink Partnrs

McKesson Corporation (NYSE:MCK) – Research analysts at Leerink Partnrs cut their Q4 2026 earnings per share (EPS) estimates for shares of McKesson in a research report issued to clients and investors on Tuesday, July 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $11.05 for the quarter, down from their prior estimate of $11.17. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share.

McKesson (NYSE:MCK) last announced its earnings results on Thursday, May 8th. The company reported $10.12 EPS for the quarter, topping the consensus estimate of $9.83 by $0.29. The company had revenue of $90.82 billion during the quarter, compared to analysts’ expectations of $94 billion. McKesson had a net margin of 0.92% and a negative return on equity of 201.12%. The business’s revenue for the quarter was up 18.9% on a year-over-year basis. During the same period last year, the company posted $6.18 earnings per share.

Several other brokerages also recently issued reports on MCK. Wells Fargo & Company set a $766.00 target price on shares of McKesson and gave the company an “equal weight” rating in a research note on Tuesday, June 3rd. Wall Street Zen raised McKesson from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 27th. Morgan Stanley raised their price objective on McKesson from $745.00 to $770.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 11th. Cfra Research downgraded McKesson from a “moderate buy” rating to a “hold” rating in a report on Friday, April 4th. Finally, UBS Group raised their price target on shares of McKesson from $708.00 to $805.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $696.42.

McKesson Stock Performance

Shares of NYSE:MCK opened at $719.30 on Wednesday. The firm has a 50 day simple moving average of $713.68 and a 200 day simple moving average of $656.07. McKesson has a 52 week low of $464.42 and a 52 week high of $736.96. The company has a market cap of $89.99 billion, a PE ratio of 27.85, a price-to-earnings-growth ratio of 1.41 and a beta of 0.48.

Institutional Trading of McKesson

Institutional investors and hedge funds have recently made changes to their positions in the stock. CVA Family Office LLC lifted its stake in shares of McKesson by 6.0% in the first quarter. CVA Family Office LLC now owns 265 shares of the company’s stock worth $178,000 after buying an additional 15 shares during the last quarter. Palisade Asset Management LLC raised its holdings in McKesson by 2.1% in the 1st quarter. Palisade Asset Management LLC now owns 715 shares of the company’s stock worth $481,000 after acquiring an additional 15 shares during the period. SteelPeak Wealth LLC lifted its position in McKesson by 0.5% during the 1st quarter. SteelPeak Wealth LLC now owns 2,771 shares of the company’s stock worth $1,867,000 after acquiring an additional 15 shares during the last quarter. Parallel Advisors LLC lifted its position in McKesson by 0.6% during the 1st quarter. Parallel Advisors LLC now owns 2,501 shares of the company’s stock worth $1,683,000 after acquiring an additional 16 shares during the last quarter. Finally, Frank Rimerman Advisors LLC boosted its holdings in McKesson by 2.2% during the fourth quarter. Frank Rimerman Advisors LLC now owns 807 shares of the company’s stock valued at $460,000 after acquiring an additional 17 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Thomas L. Rodgers sold 2,891 shares of the stock in a transaction on Friday, May 30th. The shares were sold at an average price of $712.18, for a total transaction of $2,058,912.38. Following the transaction, the executive vice president owned 2,544 shares in the company, valued at $1,811,785.92. This represents a 53.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 19,370 shares of the firm’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $705.93, for a total transaction of $13,673,864.10. Following the transaction, the chief executive officer owned 51,243 shares in the company, valued at $36,173,970.99. This represents a 27.43% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,117 shares of company stock valued at $23,526,451. 0.11% of the stock is owned by company insiders.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 1st. Shareholders of record on Monday, June 2nd were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date was Monday, June 2nd. McKesson’s dividend payout ratio (DPR) is presently 10.99%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.